The Basophil Surface Marker CD203c Identifies Aspergillus Sensitization in 2 Cystic Fibrosis
Background: Colonization by Aspergillus fumigatus in patients with cystic fibrosis (CF) can cause A fumigatus sensitization and/or allergic bronchopulmonary aspergillosis (ABPA), which affects pulmonary function and clinical outcomes. Recent studies show that specific allergens upregulate the surfac...
Saved in:
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Language: | English |
Published: |
2016
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/81769 http://hdl.handle.net/10220/39941 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Summary: | Background: Colonization by Aspergillus fumigatus in patients with cystic fibrosis (CF) can cause A fumigatus sensitization and/or allergic bronchopulmonary aspergillosis (ABPA), which affects pulmonary function and clinical outcomes. Recent studies show that specific allergens upregulate the surface-expressed basophil marker CD203c in sensitized subjects, a response that can be readily measured by using flow cytometry. Objective: We sought to identify A fumigatus sensitization in patients with CF by using the basophil activation test (BAT). Methods: Patients with CF attending Beaumont Hospital were screened for study inclusion. BAT was used to identify A fumigatus sensitization. Serologic (total and A fumigatus–specific IgE), pulmonary function, and body mass index measurements were performed. Results: The BAT discriminates A fumigatus–sensitized from nonsensitized patients with CF. Persistent isolation of A fumigatus in sputum is a significant risk factor for A fumigatus sensitization. Levels of the A fumigatus–stimulated basophil activation marker CD203c inversely correlated with pulmonary function and body mass index in A fumigatus–sensitized but not nonsensitized patients with CF. Total and A fumigatus–specific IgE, but not IgG, levels are increased in A fumigatus–sensitized patients with CF and ABPA when compared with those in A fumigatus–sensitized and nonsensitized patients with CF without ABPA. Itraconazole treatment did not affect A fumigatus sensitization. Conclusion: Combining the BAT with routine serologic testing allows classification of patients with CF into 3 groups: nonsensitized, A fumigatus–sensitized, and ABPA. Accurate and prompt identification of A fumigatus–associated clinical status might allow early and targeted therapeutic intervention, potentially improving clinical outcomes. |
---|